Adjuvant Therapy for Breast Cancer

Publisher Website
Google Scholar
Abstract
Good clinical judgment requires a balanced assessment of both a therapy's benefits and its costs, especially in terms of toxicity, in each patient. During early clinical evaluation of a new therapy, the toxic effects may be obvious and the benefits uncertain. As a result, both physician and patient may be understandably reluctant to use the therapy or even to participate in the experiment. After the first report of benefit, on the other hand, there is a danger that the new therapy may be used for every affected patient without due regard for toxicity. Many physicians have leaned alternately toward one . . .

This publication has 4 references indexed in Scilit: